P fimbria-specific B cell responses in patients with urinary tract infection
Anu Kantele1, Timo Möttönen, Kyösti Ala-Kaila
1Division of Infectious Diseases, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland. anu.kantele@hus.fi
Insights
A local immune response to P fimbria, a key factor in Escherichia coli urinary tract infections, was observed in patients with pyelonephritis. This finding supports P fimbria as a potential vaccine target for preventing kidney infections.
Area of Science:
- Immunology
- Microbiology
- Urology
Background:
- Local immune responses play a crucial role in combating urinary tract infections (UTIs).
- P fimbria, an essential virulence factor of Escherichia coli, is a promising candidate for UTI vaccine development, particularly against pyelonephritis (PN).
Purpose of the Study:
- To investigate the local immune response to P fimbria in patients with pyelonephritis (PN) and lower urinary tract infection (LUTI) caused by Escherichia coli.
- To evaluate the potential of P fimbria as a target for vaccines against UTIs.
Main Methods:
- Studied mucosa-derived antibody-secreting cells (ASCs) and urinary antibodies in eleven patients with PN and fourteen patients with LUTI.
- Analyzed the immune response to P fimbria and outer-membrane protein A in patients infected with either P-fimbriated (P+) or non-P-fimbriated (P-) E. coli.
Main Results:
- An ASC response to P fimbria was detected in all five PN patients with P+ E. coli and one of five LUTI patients with P+ E. coli.
- The immune response to P fimbria was significantly stronger in patients with P+ PN compared to those with P- PN or P+ LUTI.
- P fimbria-specific urinary immunoglobulin A levels were elevated in patients with P+ PN compared to those with P- PN.
Conclusions:
- A P fimbria-specific local immune response is evident in patients with pyelonephritis.
- These findings strongly support the use of P fimbria in the development of locally administered vaccines for UTIs.
Abstract:
Local immune response may be important in defense against urinary tract infection (UTI). P fimbria, an important virulence factor of Escherichia coli, is a noteworthy candidate for use in a vaccine against pyelonephritis (PN). Eleven patients with PN and 14 patients with lower urinary tract infection (LUTI) caused by E. coli were studied for mucosa-derived antibody-secreting cells (ASCs) and for urinary antibodies. In the 10 patients with P-fimbriated (P+) E. coli, an ASC response to P fimbria was found in 5 of 5 patients who had PN and 1 of 5 patients who had LUTI. The response to P fimbria was stronger among patients with P+ PN than among patients with PN caused by non-P-fimbriated E. coli (P-) (P<.001) or patients with P+ LUTI (P<.001). The response to P fimbria was also stronger than the response to outer-membrane protein A among all patients with PN. P fimbria-specific urinary immunoglobulin A antibody levels were higher among patients with P+ PN than those with P- PN. The results show a P fimbria-specific local immune response, which further encourages the use of P fimbria in locally administrable UTI vaccines.
Related Concept Videos
Urinary Tract Infection II: Pathophysiology
Fimbriae, Pili, and Axial Filaments
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Urinary Tract Infection I: Introduction
Urine Studies II: Urine Culture and Sensitivity Test
Microbiota of the Urogenital Tract


